Monrovia, California (PressExposure) September 19, 2012 -- Michael Kalos, Director of Translational and Correlative Studies Laboratory at the University of Pennsylvania, will be giving a presentation on 'T cell Immunotherapy of Cancer at UPenn: an Academic model for Translational Excellence' at GTC's 4th Translational Medicine conference (October 24th-26th, 2012 in Philadelphia, PA)
The successful establishment of translational research programs in academia and the private sector requires the effective integration of multiple and often disparate entities. In this presentation we will discuss the T cell Immunotherapy program at the University of Pennsylvania, a translational program with demonstrable success in the translation of novel T cell based therapies into the clinic. Specifically, we will discuss infrastructure elements whose implementation has been crucial for the successful establishment of this program, and discuss specific examples of the successful translation of novel therapies from the bench to the bedside.
Dr. Kalos is a graduate of the University of Minnesota Medical School. Following two postdoctoral fellowships at the Fred Hutchinson Cancer Research Center, Dr. Kalos moved to Corixa Corporation, a biotechnology company in Seattle, where he played an instrumental role in the discovery and pre-clinical evaluation of novel cancer vaccines for prostate and lung cancer, work that led to a number of issued patents.
Following his tenure at Corixa, Dr. Kalos moved to City of Hope as the founding director of the Clinical Immunobiology Correlative Studies Laboratory (CICSL), a GLP-level laboratory that focused on the development and application of integrated molecular, flow-based, and biochemical biomarker assays.
In 2008 Dr. Kalos was recruited to the University of Pennsylvania where, as Founding Director of the Translational and Correlative Studies laboratory where he is involved in the translational/clinical development and biomarker evaluation of novel cell based immunotherapeutics.
Dr. Kalos has authored multiple primary, review articles, and book chapters in the field of cancer immunotherapy, and is a member of the steering committees for international immune monitoring working groups
The 4th Translation Medicine Conference is part of our 8th Modern Drug Discovery & Development Summit. Other tracks for this summit include:
8th Modern Drug Discovery & Development Summit
(Day 1, Oct 24, 2012) - Plenary Keynote Session
(Day 2-3, Oct 25-26, 2012) - Breakout Tracks:
7th Assay & Drug Discovery Technologies
9th Stem Cell Research & Therapeutics
3rd Pharmacokinetics & Pharmacodynamics
Biotechnology Transfer & Commercialization
For more information, please visit http://www.gtcbio.com/tmed